<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prognostic relevance of miRNA-155 methylation in anaplastic glioma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-11-18">November 18, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Maximilian</forename><forename type="middle">Georg</forename><surname>Schliesser</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainer</forename><surname>Claus</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Epigenomics and Cancer Risk Factors</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department">Department Hematology, Oncology and Stem Cell Transplantation</orgName>
								<orgName type="institution">University Hospital Freiburg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Hielscher</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Biostatistics</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christiane</forename><surname>Grimm</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dieter</forename><surname>Weichenhan</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Epigenomics and Cancer Risk Factors</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jonas</forename><surname>Blaes</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Benedikt</forename><surname>Wiestler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff23">
								<orgName type="department">Department of Diagnostic and Interventional Neuroradiology</orgName>
								<orgName type="laboratory">Klinikum rechts der Isar</orgName>
								<orgName type="institution">Technischen Universität München</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Hau</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">Neurology Clinic</orgName>
								<orgName type="institution" key="instit2">Regensburg University</orgName>
								<address>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><surname>Schramm</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Neurosurgery Clinic</orgName>
								<orgName type="institution" key="instit2">University of Bonn Medical Center</orgName>
								<orgName type="institution" key="instit3">TU Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Felix</forename><surname>Sahm</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Neuropathology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisa</forename><forename type="middle">K</forename><surname>Weiß</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Weiler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of General Neurology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Constance</forename><surname>Baer</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Epigenomics and Cancer Risk Factors</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Friederike</forename><surname>Schmidt-Graf</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of General Neurology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">Neurology Clinic, TU Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriele</forename><surname>Schackert</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution" key="instit1">Neurosurgery Clinic</orgName>
								<orgName type="institution" key="instit2">Dresden University Medical Center</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Manfred</forename><surname>Westphal</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution" key="instit1">Neurosurgery Clinic</orgName>
								<orgName type="institution" key="instit2">University Clinic Hamburg</orgName>
								<address>
									<settlement>Eppendorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anne</forename><surname>Hertenstein</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Roth</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of General Neurology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Norbert</forename><surname>Galldiks</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution" key="instit1">Neurology Clinic</orgName>
								<orgName type="institution" key="instit2">Cologne University</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Hartmann</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Neuropathology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Department for Neuropathology</orgName>
								<orgName type="department" key="dep2">Institute of Pathology</orgName>
								<orgName type="institution">Medical University of Hannover</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Torsten</forename><surname>Pietsch</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">University of Bonn Medical Center</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joerg</forename><surname>Felsberg</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">DKTK</orgName>
								<address>
									<addrLine>Partner Site Essen/Düsseldorf</addrLine>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Guido</forename><surname>Reifenberger</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">DKTK</orgName>
								<address>
									<addrLine>Partner Site Essen/Düsseldorf</addrLine>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">Christoph</forename><surname>Sabel</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Neurosurgery</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Winkler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Von Deimling</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Neuropathology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neuropathology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Meisner</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Biostatistics</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Vajkoczy</surname></persName>
							<affiliation key="aff21">
								<orgName type="institution">Neurosurgery Clinic</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Platten</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neuroimmunology and Brain Tumor Immunology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of General Neurology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Weller</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of General Neurology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Plass</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Epigenomics and Cancer Risk Factors</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Wolfgang</forename><surname>Wick</surname></persName>
							<email>wolfgang.wick@med.uni-heidelberg.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Clinical Cooperation Units</orgName>
								<orgName type="institution">Heidelberg University Hospital and German Cancer Consortium</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Clinical Cooperation Unit of Neurooncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of General Neurology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Prognostic relevance of miRNA-155 methylation in anaplastic glioma</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-11-18">November 18, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">2C864ADC1855BBE45A813ABAC2397863</idno>
					<note type="submission">Received: May 09, 2016 Accepted: September 13, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>anaplastic glioma</term>
					<term>miR-155</term>
					<term>IDH</term>
					<term>NFκB</term>
					<term>NOA-04</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The outcome of patients with anaplastic gliomas varies considerably depending on single molecular markers, such as mutations of the isocitrate dehydrogenase (IDH)</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Anaplastic gliomas of World Health Organization (WHO) grade III are currently subdivided into anaplastic astrocytic and oligodendroglial (and mixed) tumors <ref type="bibr" target="#b0">[1]</ref>.</s><s>The considerable interobserver variation for grading and typing of gliomas <ref type="bibr" target="#b1">[2]</ref>, the variability of outcomes within the subgroups and a paucity of therapeutically attractive targets derived from this framework have triggered studies suggesting a molecularly-based classification for grade II and III gliomas.</s><s>This histological classification and the underlying mutations in the isocitrate dehydrogenase (IDH) genes 1 and 2 resulting in a glioma CpG island methylator phenotype (GCIMP) <ref type="bibr" target="#b2">[3]</ref>, 1p/19q co-deletions, as well as mutually exclusive mutations in telomerase reverse transcriptase (TERT) and alpha-thalassemia/ mental retardation syndrome X-linked (ATRX) genes <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref> are providing a clinically useful prognostic framework <ref type="bibr" target="#b6">[6]</ref>.</s><s>Indeed, gliomas across histological subtypes with an IDH mutation carry a very similar epigenetic profile <ref type="bibr" target="#b7">[7]</ref>.</s><s>This and other studies <ref type="bibr" target="#b8">[8]</ref> suggest that IDH mutant gliomas form a biologically distinct entity.</s><s>However, there is still value to the WHO grading <ref type="bibr" target="#b52">[52]</ref> and a need for deeper understanding of the molecular biology of gliomas outside the known genetic, epigenetic and transcriptional changes.</s><s>Noteworthy, the majority of transcripts within a cell does not represent protein-coding but actually non-coding RNA (ncRNA) <ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref>.</s><s>Amongst those, miRNA gained major attraction as they act as mainly inhibitory modifiers of translation by steric hindrance of the ribosome or by prompting the mRNA degradation <ref type="bibr" target="#b12">[12,</ref><ref type="bibr" target="#b13">13]</ref> which are of paramount relevance in cancer <ref type="bibr" target="#b14">[14]</ref>.</s><s>In a tumor setting the phenotypic effect of miRNAs depends on the function of the inhibited mRNAs.</s></p><p><s>The aim of the present work was to better understand the transcriptional regulation of miRNAs in gliomas, find novel survival marker as well as treatment options.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differential methylation of miRNAs in anaplastic gliomas</head><p><s>The overlay of differentially methylated regions (DMRs) detected in tissue samples from the NOA-04 trial and putative miRNA promoter regions generated an initial list of 29 differentially methylated candidate miRNA promoter regions.</s><s>The DMR data set was derived from a MCIp-based DNA methylation profiling and the promoter set had been previously identified in an H3K4me3 ChIP screen <ref type="bibr" target="#b18">[18]</ref>.</s><s>The candidates were prioritized and checked for promoter activity taking into account additional factors: a favorable distance and orientation of the miRNA gene, adjacent CpG islands, the degree of DNase hypersensitivity and vertebrate conservation of the target region.</s><s>The 12 most promising miRNA-associated candidate regions with differential methylation in anaplastic gliomas were selected for indepth analysis (Figure <ref type="figure" target="#fig_0">1</ref>, Supplementary Figure <ref type="figure" target="#fig_0">1</ref>) and validated by quantitative DNA methylation analysis using the MassARRAY technology.</s></p><p><s>genes, as well as molecular classifications based on epigenetic or genetic profiles.</s><s>Remarkably, 98% of the RNA within a cell is not translated into proteins.</s><s>Of those, especially microRNAs (miRNAs) have been shown not only to have a major influence on physiologic processes but also to be deregulated and prognostic in malignancies.</s></p><p><s>To find novel survival markers and treatment options we performed unbiased DNA methylation screens that revealed 12 putative miRNA promoter regions with differential DNA methylation in anaplastic gliomas.</s><s>Methylation of these candidate regions was validated in different independent patient cohorts revealing a set of miRNA promoter regions with prognostic relevance across data sets.</s><s>Of those, miR-155 promoter methylation and miR-155 expression were negatively correlated and especially the methylation showed superior correlation with patient survival compared to established biomarkers.</s></p><p><s>Functional examinations in malignant glioma cells further cemented the relevance of miR-155 for tumor cell viability with transient and stable modifications indicating an onco-miRNA activity.</s><s>MiR-155 also conferred resistance towards alkylating temozolomide and radiotherapy as consequence of nuclear factor (NF)κB activation.</s></p><p><s>Preconditioning glioma cells with an NFκB inhibitor reduced therapy resistance of miR-155 overexpressing cells.</s><s>These cells resembled tumors with a low methylation of the miR-155 promoter and thus mir-155 or NFκB inhibition may provide treatment options with a special focus on patients with IDH wild type tumors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prognostic relevance of miRNA methylation in anaplastic gliomas</head><p><s>The candidate regions were first analyzed in 106 patients with anaplastic gliomas from the NOA-04 trial (Table <ref type="table">1</ref>, Supplementary Figure <ref type="figure" target="#fig_1">2</ref>, Figure <ref type="figure" target="#fig_1">2A</ref>; see Supplement for patients' characteristics).</s><s>The full statistics with all analyzed CpGs and amplicons is available in Supplementary Table <ref type="table">1</ref>.</s><s>Due to differences in the sample, amplicon and procedure quality reduced number of patients with methylation data are present for different miRNA candidates of the same patient cohort.</s><s>For all DMR, except the one associated with miR-10b, a high methylation was associated with a longer progression free survival (PFS) and overall survival (OS).</s><s>The prognostic relevance of selected regions was validated in an independent anaplastic glioma patient samples (n = 82) from the GGN <ref type="bibr" target="#b16">[16]</ref> using the same primers and settings as for the initial NOA-04 patients.</s><s>In the confirmatory analysis, low methylation levels at the miR-155 and miR-210 promoters were significantly associated with worse PFS and OS (Table <ref type="table">1</ref>, Supplementary Figure <ref type="figure" target="#fig_2">3</ref>; see Supplement for patients' characteristics).</s><s>Methylation levels of the miR-335 promoter region were merely correlated with OS.</s></p><p><s>Correlation with clinically relevant markers showed that IDH mutation with the CpG island methylator phenotype (CIMP), 1p/19q codeletion, MGMT promoter methylation and oligodendroglial histology were associated with high miRNA-associated 5'-region methylation levels (Figure <ref type="figure" target="#fig_1">2B</ref>).</s></p><p><s>Furthermore, the relevance of miRNA promoter methylation for patients with anaplastic glioma was assessed in data available from The Cancer Genome Atlas (TCGA).</s><s>The analysis on TCGA data confirmed the negative correlation for miR-155-associated methylation in WHO grade III glioma and also showed a lower but significant correlation for methylation of the miR-335 promoter region (Figure <ref type="figure" target="#fig_1">2C</ref>).</s><s>Likewise, also the correlation with clinical markers resembled the NOA-04 situation (Figure <ref type="figure" target="#fig_1">2D</ref>).</s></p><p><s>In order to test a differential impact on radio-or chemotherapy, samples from NOA-04 patients were split according to the first line treatment, which showed that the survival advantage of the candidate methylation sites was independent of treatment modality (first line chemoor radiotherapy) (Supplementary Figure <ref type="figure" target="#fig_3">4</ref>).</s><s>To assess an age-or WHO grade-related effect, candidate regions were tested on 101 patient samples from the NOA-8 trial for patients &gt; 65 years of age with mainly glioblastoma (89 %) or anaplastic astrocytoma (11 %) <ref type="bibr" target="#b15">[15]</ref>.</s><s>In these patients no correlation of the miRNA methylation status with survival was seen (Supplementary Table <ref type="table">2</ref>).</s></p><p><s>Moreover, testing the prognostic relevance of the miR-155-, miR-210-and miR-335-associated 5' region DNA methylation in glioblastoma data available from TCGA did not produce significant results for WHO grade IV patients (Supplementary Table <ref type="table">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Correlation of miRNA-associated DNA methylation and miRNA expression</head><p><s>Having established and validated the prognostic relevance of differential miR-155, miR-210 and miR-335 promoter region methylation, we aimed at deciphering the functional impact of DNA methylation differences.</s><s>MiRNA promoter methylation and miRNA expression were assessed in 12 fresh frozen glioma samples (Figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>For all candidates the major mature form of the respective miRNA transcript was analyzed and if not otherwise specified, the miRNA name refers to this form throughout the paper (miR-155 for miR-155-5p, miR-210 for miR-210-3p and miR-335 for miR-335-5p).</s></p><p><s>High methylation at the miR-155 promoter region was linked to low miRNA expression.</s><s>In addition, the correlation of methylation and expression was performed with anaplastic glioma patient data available from TCGA, which verified the negative correlation for miR-155 and also showed a weaker but significant correlation for miR-335 (Figure <ref type="figure" target="#fig_2">3B</ref>).</s><s>Moreover, TCGA data showed that miR-155 expression is prognostic and that anaplastic glioma patients with a high miR-155 expression feature a poor survival (Figure <ref type="figure" target="#fig_2">3C</ref>).</s></p><p><s>Relevance of promoter methylation for miRNA expression was also shown in cell lines.</s><s>Decitabine (5-aza-2'-deoxycytidine) was applied and DNA methylation was determined by MassARRAY and miRNA expression by qPCR (Supplementary Figure <ref type="figure" target="#fig_5">5, 6</ref>).</s><s>Cells with an initially low miR-155 expression but high methylation of the miR-155 promoter region (T98G and U251MG) showed a strong increase in miR-155 expression after demethylation.</s><s>For miR-335 also an increase from low to higher expression was seen after decitabine treatment of highly methylated cell lines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>miR-155 promoter methylation and expression is superior to established prognostic markers</head><p><s>In the next step, miRNA markers were analyzed in a multivariable analysis on PFS imputing all significant co-variables form the NOA-04 trial, namely histology, first-line therapy, IDH mutation and MGMT promoter methylation status.</s><s>Putative promoter methylation of miR-155 and miR-210 were the only significant prognostic factors in the respective analyses (Figure <ref type="figure" target="#fig_3">4A</ref>).</s><s>PFS was preferred over OS for the NOA-04 calculations since the number of OS events is still too low.</s><s>In addition, we analyzed the TCGA data taking IDH status into account (Figure <ref type="figure" target="#fig_3">4B</ref>).</s><s>Both, miR-155 promoter methylation and miR-155 expression were significant prognosticators in this calculation, while methylation and expression of miR-210 and miR-335 were not.</s><s>), IDH mutation status, MGMT promoter methylation status, histopathology and first line treatment were taken into account for the NOA-04 patients (A).</s><s>From the TCGA data set the miRNA methylation and miRNA expression (expr.)</s><s>were compared against the IDH mutation status (B).</s><s>Significant correlations were denoted in grey (p-value &lt; 0.05).</s><s>Both multivariable analyses were additionally performed using the molecular classification with CpG island methylator phenotype (CIMP) and 1p/19q codeletion status (Supplementary Table <ref type="table">4</ref>) <ref type="bibr" target="#b28">[28]</ref>.</s><s>Apart from the uni-and mulitvariable Cox regression analysis and all patients, also the Hazard ratio of the miR-155 promoter methylation (per 10% methylation increase) was calculated for the IDH wildtype and mutant patients of the NOA-04 cohort and the TCGA data.</s><s>HazR: Hazard ratio; CI: confidence interval; mut: mutated; wt: wild type; m: methylated; u: unmethylated; O(A): oligodendroglioma and oligoastrocytoma; A: astrocytoma; RT: radiotherapy; CT: chemotherapy; n: number of patients with data for all five factors; events: number of patients with progress/death.</s></p><p><s>Additionally for both NOA-04 and TCGA patients, the miRNA methylation markers were analyzed applying the newly established molecular classification <ref type="bibr" target="#b28">[28]</ref> (Supplementary Table <ref type="table">4</ref>).</s><s>Also in this multivariable analysis miR-155 promoter methylation was superior.</s></p><p><s>The calculations based on the GGN patient cohort investigated here were not significant in the multivariable Cox analysis (Supplementary Table <ref type="table">5</ref>).</s><s>However, when the prognostic relevance of IDH mutation status and MGMT promoter methylation were tested by univariable Cox analysis in this cohort, both were not significant (Supplementary Table <ref type="table">5</ref>).</s><s>This strongly indicates a nonregular patient distribution in the investigated subset of the GGN cohort concerning these established markers.</s><s>Thus, the multivariable analysis on the GGN patients is to be handled with care.</s></p><p><s>To further determine the IDH independent relevance of miR-155 the prognostic value of miR-155 was not only analyzed by univariable and multivariable Cox regression on all patients but also after separation into IDH wild type and IDH mutant patients (Figure <ref type="figure" target="#fig_3">4C</ref>).</s><s>In the IDH wild type patients of the NOA-04 and TCGA cohorts, miR-155 promoter methylation still suggests prognostic relevance.</s><s>In this patient group also a highly differential miR-155 expression had been observed (Figure <ref type="figure" target="#fig_1">2B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>miR-155 is active as onco-miRNA</head><p><s>After establishing miR-155 as strong prognostic marker, even in comparison to established markers, the aim was to better understand the biology behind miR-155 and deduce its role for reduced patient survival.</s><s>Glioma cell (U87MG, A172 and LN-428) viability was markedly reduced after miR-155 levels were transiently knocked down by siRNA (Figure <ref type="figure" target="#fig_4">5A</ref>, Supplementary Figure <ref type="figure" target="#fig_6">7</ref>).</s></p><p><s>For in-depth functional analyses a stable overexpression of miR-155 in the glioma cell line T98G was established (Supplementary Figure <ref type="figure" target="#fig_7">8</ref>) and the proliferation and clonogenicity analyzed in the presence of temozolomide and radiotherapy (Figure <ref type="figure" target="#fig_4">5C-5F</ref>).</s><s>Proliferation and clonogenicity assays revealed that miR-155 confers resistance to both treatment modalities.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>miR-155 as master modulator induces NFκB activity</head><p><s>To further elucidate the effect of miR-155 overexpression in glioma cells the transcriptional changes upon miR-155 expression were analyzed in vitro and in patient-derived tissue data.</s><s>To capture the latter, the anaplastic glioma TCGA data was used to determine which genes were positively or negatively expressed together with miR-155.</s><s>Since recent data of our group <ref type="bibr" target="#b29">[29]</ref> and others <ref type="bibr" target="#b30">[30]</ref><ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref> indicate that the IDH or GCIMP status separates two distinct patient groups, tissues were split into IDH wild type and IDH mutant tumors.</s><s>Especially in the IDH wild type patients a high number of genes were found whose expression was either positively (0.4 to 1) or negatively (-1 to -0.4) correlated to the expression of miR-155 (Figure <ref type="figure" target="#fig_5">6A</ref>).</s><s>This patient group had initially also featured a differential miR-155 promoter methylation in contrast to the IDH mutant tumors, which had a uniformly high miR-155 promoter methylation (Figure <ref type="figure" target="#fig_1">2B</ref>).</s></p><p><s>For the in vitro situation microarray expression analyses were performed with the control and miR-155 overexpressing cells after mock treatment and chemo-or radiotherapy showing a high number of transcriptional changes upon miR-155 expression in the heatmap (Figure <ref type="figure" target="#fig_5">6B</ref>).</s></p><p><s>Combining cell line and patient data sets revealed several genes with coregulation (Figure <ref type="figure" target="#fig_5">6C</ref>).</s><s>The genes present in the table were additionally all validated by qPCR in the cell line.</s><s>Three genes were consistently strongly deregulated upon stable in vitro miR-155 expression and in the miR-155 expressing IDH wild type tumors: brain-expressed X-linked protein (BEX)1, atlastin (ATL)1 and tetraspanin (TSPAN)7 (Figure <ref type="figure" target="#fig_5">6C</ref>).</s><s>Yet, these genes were not found to be direct canonical miR-155 targets in different miRNA target predictions (miRTarBase, targetscan, TarBase, miRDB and Pictar).</s><s>To elucidate the underlying miR-155 molecular pathway effects, transcriptome data was analyzed by Ingenuity Pathway Analysis (IPA) indicating activation of the NFκB pathway upon miR-155 expression (Figure <ref type="figure" target="#fig_6">7A</ref>).</s><s>This was confirmed by immunoblot analysis for the phosphorylation of the NFκB subunit p65, marker for an active canonical NFκB pathway, in the control and miR-155 overexpressing cells (Figure <ref type="figure" target="#fig_6">7B</ref>).</s><s>Moreover, pretreating glioma cells with the NFκB inhibitor JSH-23 specifically reduced therapy resistance in miR-155 overexpressing cells (Figure <ref type="figure" target="#fig_6">7C</ref>).</s><s>Apart from the NFκB inhibitor BEX1 determined above, it was recently published that NFκB inhibitor interacting Ras-like 1 (NKIRAS1) is a direct target of miR-155 <ref type="bibr" target="#b33">[33]</ref>.</s><s>Although the reduction at the RNA level was only marginal in the miR-155 expressing cells, immunoblot analysis showed a strong reduction of NKIRAS1 at the protein level after miR-155 overexpression (Figure <ref type="figure" target="#fig_6">7D, 7E</ref>).</s><s>Moreover, in IDH wild type anaplastic glioma patients NKIRAS1 expression was negatively correlated with miR-155 expression at the RNA level (Figure <ref type="figure" target="#fig_6">7D</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In this NOA-04 dataset-based epigenome-wide DNA methylation screen, methylation of the miR-155 promoter was established as strong prognostic marker in patients with anaplastic gliomas in three independent patient cohorts.</s><s>Mir-55 promoter methylation showed stronger effects than IDH mutation status, MGMT promoter methylation and histopathology.</s><s>In functional analyses the onco-miRNA activity of miR-155 was confirmed and the promotion of therapy resistance upon miR-155 expression was associated with increased NFκB activity.</s></p><p><s>Several recent studies <ref type="bibr" target="#b30">[30]</ref><ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref> have established a classification for anaplastic gliomas consisting of three classes, separable by IDH mutation or GCIMP and 1p/19q deletion status as well as presence of absence of copy number variations typical for glioblastoma.</s><s>Importantly, this molecular classification signifies clinically relevant survival differences and is superior to the current histopathological subtyping <ref type="bibr" target="#b29">[29]</ref>.</s><s>The present study focussed on differentially methylated candidates outside IDH and 1p/19q in the non-coding regions of the DNA.</s></p><p><s>The advantage of methylation biomarkers lays in the easy determination by pyrosequencing / MassARRAY and putative stability over time.</s><s>In chronic lymphocytic leukemia DNA methylation of a single CpG in the promoter of ZAP-70 predicts the outcome <ref type="bibr" target="#b34">[34,</ref><ref type="bibr" target="#b35">35]</ref>.</s><s>Similarly, an HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas <ref type="bibr" target="#b36">[36]</ref>.</s></p><p><s>Independent from later miRNA studies already the primary transcript of miR-155, B-cell integration cluster (BIC), was marked as proto-oncogene in chicken B-cell lymphomas induced by the avian leukosis virus <ref type="bibr" target="#b37">[37,</ref><ref type="bibr" target="#b38">38]</ref>.</s><s>With the upcoming miRNA research, the mature miR-155 was deducted from BIC also in mouse and human <ref type="bibr" target="#b39">[39]</ref>.</s><s>The antisense strand of the miR-155 duplex (miR-155-3p), which is expressed only at minor levels in comparison to miR-155 (miR-155-5p) <ref type="bibr" target="#b40">[40,</ref><ref type="bibr" target="#b41">41]</ref>.</s><s>miR-155 was found to be overexpressed in leukemia and lymphoma, but also in solid tumors of the lung and breast as well as in glioma <ref type="bibr" target="#b42">[42]</ref>.</s></p><p><s>The functional data with transient and stable miR-155 expression modulations are in line with the so far only transient anti-miR-155 siRNA studies.</s><s>U87MG showed reduced proliferation upon miR-155 inhibition with unmodified siRNAs, as well as a diminished migration and invasion but increased apoptosis <ref type="bibr" target="#b43">[43]</ref><ref type="bibr" target="#b44">[44]</ref><ref type="bibr" target="#b45">[45]</ref>.</s><s>Also miR-155 knockdown in U251MG cells resulted in reduced proliferation and enhanced chemo-sensitivity <ref type="bibr" target="#b46">[46]</ref>.</s><s>However, in our hands U251 belonged to the group of cell lines with a high methylation and minimal miR-155 expression levels <ref type="bibr" target="#b43">[43]</ref><ref type="bibr" target="#b44">[44]</ref><ref type="bibr" target="#b45">[45]</ref>.</s></p><p><s>One initial drawback of the analyses was the existence of the GCIMP in IDH mutated gliomas <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b47">47]</ref>, which rendered differential methylation of most attractive candidates in the past just an epiphenomenon of co-methylation despite the potential functional or clinical relevance.</s><s>Here, we identified a candidate, miR-155, which showed prognostically relevant differential promoter methylation in anaplastic gliomas superior to established marker.</s><s>This makes miR-155 a particularly attractive candidate since apart from MGMT there is no other DNA methylation-regulated candidate marker with relevance outside the IDH-effect.</s><s>The mechanisms, by which MGMT and miR-155 are regulated, remain to be determined <ref type="bibr" target="#b48">[48]</ref>.</s></p><p><s>Interestingly, the analysis of TCGA glioblastoma patients, who are mainly IDH wild type patients, did not reveal prognostically relevant differential miR-155 promoter methylation (Supplementary Table <ref type="table">3</ref>), indicating a marker with some selectivity for anaplastic glioma.</s><s>The same was seen for malignant gliomas in elderly patients (Supplementary Table <ref type="table">2</ref>).</s><s>This patient group with nearly no IDH mutations had been shown to be especially troublesome, since the generally low DNA methylation levels in their tumors prevented proposed gene candidates from being prognostic <ref type="bibr" target="#b49">[49]</ref>.</s></p><p><s>One of the earliest onco-miRNA representative is miR-21, whose aberrant expression was first described in a miRNA screen on glioblastoma patient samples yielding miR-21 as the candidate showing strongest upregulation in glioblastoma and demonstrating a functional dependency of glioblastoma cells on its expression <ref type="bibr" target="#b50">[50]</ref>.</s><s>Apart from miR-155 also other miRNAs with promising results in our methylation screen, like miR-210 and miR-335, have been determined as functional onco-miRNA in glioma <ref type="bibr" target="#b51">[51,</ref><ref type="bibr" target="#b52">52]</ref>.</s><s>Moreover, the TCGA studies on large cohorts of patients with glioblastoma, followed by numerous articles making use of the publically available data, and recently WHO grade II and III glioma highlight the deregulation and involvement of multiple miRNAs species in gliomas <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b53">53,</ref><ref type="bibr" target="#b54">54]</ref>.</s></p><p><s>Limitations to our data are the retrospective nature of the analyses as well as the multiple analyses performed on the NOA-04 biomarker data set.</s><s>To overcome these limitations, data were corrected for multiple testing and stringent criteria were used for the confirmation of the data in independent cohorts.</s><s>Starting from two unsupervised analyses, candidates were narrowed down by challenging in other datasets and finally cell line experiments.</s><s>Therefore, it cannot be excluded that though aiming to be comprehensive, we may have omitted candidates that may be of value.</s><s>Sample size especially with focus on event rates and numbers in the individual subgroups, although considerable in total, may have been too low to decipher predictive effects of miR-155 or any other candidates.</s><s>As opposed to TCGA and NOA-04, the subpopulation of the GGN cohort investigated in this study did not feature a known distribution of the established biomarker IDH mutation and MGMT promoter methylation (Supplementary Table <ref type="table">5</ref>).</s><s>The consistent prognostic value of miR-155 promoter methylation in this cohort further underlines its relevance even beyond the clinical study situation (NOA-04) and research oriented patient selection (TCGA).</s></p><p><s>Besides, the cut-off methylation level of 67% methylation at the miR-155 promoter, applied to split the patients into the "low" and the "high" methylated group, was determined statistically to generate the Table <ref type="table">1</ref>: Prognostic miRNA promoter methylation was determined for patients with anaplastic gliomas of the NOA-04 trial and validated in a GGN cohort.</s></p><p><s>The methylation of the candidate regions was analyzed by MassARRAY in patient samples of the NOA-04 cohort <ref type="bibr" target="#b51">[51]</ref> and afterwards validated in patients from the GGN <ref type="bibr" target="#b49">[49]</ref>.</s><s>By a Cox regression model the mean methylation of each candidate region was correlated with the progression free and overall survival and the p-value corrected for testing of multiple candidates.</s><s>Significant correlations were denoted in grey (adj.</s><s>p-value &lt; 0.05).</s><s>The results for all analyzed CpGs and amplicons is given in the supplement.</s><s>Obs: observation, number of patients with full data; HazR: Hazard ratio; CI: confidence interval; p-value adj: p-value adjusted for testing of multiple amplicons and CpG fragments strongest significance in the NOA-04 cohort (Figure <ref type="figure" target="#fig_1">2</ref>).</s><s>Consequently, although this cut-off value was subsequently confirmed in the GGN cohort (Supplementary Figure <ref type="figure" target="#fig_2">3</ref>), further validation and presumably adjustment are necessary, to best serve the actual patient situation.</s><s>The choice of glioblastoma cell lines instead of cell lines from anaplastic gliomas was made based on the limited availability of manageable WHO grade III cells in culture and the strong effect of miR-155 in IDH wild type anaplastic gliomas.</s><s>Future challenges will be the integration of information of this kind into prospective trials and later into the glioma classification and the present set of clinically applicable biomarkers.</s><s>Moreover, a proofof-concept clinical trial is needed to address the value of NFκB or even more distal inhibition in the treatment of patients with miR-155 overexpressing gliomas.</s><s>Yet, miRNA-based treatments are coming of age and are entering the clinic.</s><s>Miravirsen, a miR-122 antisense therapy for hepatitis C with hepatitis C virus infection, has recently shown promising results in a phase 2a trial <ref type="bibr" target="#b55">[55]</ref>.</s><s>Additionally, the first miRNA-based cancer therapy MRX34 is in the late stage of a phase I trial on liver cancer and liver metastasis <ref type="bibr" target="#b56">[56]</ref>.</s><s>The blood-brain-barrier constitutes a major hurdle for the treatment of gliomas but already several strategies are pursued with exosome / liposome particles, polymer based vectors and viral systems being at a special focus nowadays <ref type="bibr" target="#b57">[57]</ref><ref type="bibr" target="#b58">[58]</ref><ref type="bibr" target="#b59">[59]</ref>.</s></p><p><s>For testing of miR-155 promoter methylation levels, the technically easiest and least tissue consuming analyses would be MassARRAY technology or pyrosequencing, both being applicable to formalin-fixed paraffin embedded tumor tissue <ref type="bibr" target="#b19">[19]</ref>.</s><s>Methylation specific PCR is not recommended since it does not generate quantitative results but only produces a binary output: unmethylated or methylated <ref type="bibr" target="#b60">[60]</ref>.</s></p><p><s>In summary (Figure <ref type="figure" target="#fig_7">8</ref>), miR-155 promoter methylation and anaplastic glioma patient survival were correlated and a lower miR-155 promoter methylation was associated with worse prognosis.</s><s>We further observed that miR-155 promoter methylation and miR-155 expression were negatively correlated, and that high promoter methylation reduced the expression of miR-155.</s><s>Further, high miR-155 expression was associated with strong transcriptional changes and NFκB pathway activation mediating chemo-and radiotherapy resistance.</s><s>We hypothesize that these observations explain why patients with anaplastic gliomas featuring high miR-155 expression demonstrate reduced survival.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and tumor samples</head><p><s>Glioma tissue samples were acquired from the two clinical trials NOA-04 and NOA-08 and additionally the prospective cohort study of the German Glioma Network (GGN).</s><s>The clinically related research in this work is covered by the ethics votes for NOA-04 <ref type="bibr" target="#b6">[6]</ref>, NOA-08 <ref type="bibr" target="#b15">[15]</ref> and the GGN <ref type="bibr" target="#b16">[16]</ref> (for molecular characteristics see the supplement).</s></p><p><s>As opposed to TCGA and NOA-04, the subpopulation of the GGN cohort investigated in this study did not show a known distribution of the established biomarker IDH mutation and MGMT promoter methylation (Supplementary Table <ref type="table">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Purification of DNA and RNA</head><p><s>DNA from formalin fixed paraffin embedded patient tissue was purified from representative tumor areas with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).</s></p><p><s>DNA together with RNA &gt; 200 bp and RNA &lt; 200 bp was purified from fresh frozen patient tissue and cell lines with the AllPrep DNA/RNA Mini Kit (Qiagen) together with the RNeasy MinElute Cleanup Kit (Qiagen) according protocol to the standard protocol.</s><s>For samples where DNA was not needed, then miRNAs were purified with the miRNeasy Mini Kit (Qiagen, Hilden, Germany) together with the RNeasy MinElute Cleanup Kit (Qiagen) to obtain an RNA fraction &lt; 200 bp and &gt; 200 bp.</s><s>For an extraction of only RNA &gt; 200 bp, the RNeasy Kit (Qiagen) was used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methyl-CpG immunoprecipitation (MCIp) and CpG island array hybridization</head><p><s>Methyl-CpG immunoprecipitation (MCIp) with 2.5 μg genomic DNA, array hybridization using CpG island arrays (Agilent, Waldbronn, Germany) and data evaluation were essentially performed as described previously <ref type="bibr" target="#b17">[17]</ref>.</s><s>Enrichment of methylated DNA fragments was controlled by qPCR analyzing the differentially methylated sequence in the gene PCDHGA11 and on the other hand GAPDH as a marker for unmethylated fragments.</s><s>Differentially methylated regions (DMRs) were defined and identified as described <ref type="bibr" target="#b17">[17]</ref>.</s><s>The array data have been deposited in NCBI's Gene Expression Omnibus under accession number GSE79080.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MiRNA promoter data and generation of differentially methylated miRNA promoter candidates from data set overlay</head><p><s>For miRNA promoter identification, the H3K4me3 ChIP data set previously published by Baer et al <ref type="bibr" target="#b18">[18]</ref> was utilized.</s><s>These data were generated using an Agilent custom-design 244k array covering genomic loci of 939 annotated miRNAs from miRBase 15 (http://www.</s><s>mirbase.org/).</s><s>The sequences represented on the array included 35 kb upstream and 5 kb downstream of the pre-miRNAs and 2 kb up-and downstream of transcriptional start sites of miRNA hosting genes.</s><s>The array design is available at Agilent's array platform (AMADID029434 for hg19).</s><s>Analysis of H3K4me3 ChIP data was performed with the CoCAS ChIP-on-chip analysis suite as described previously <ref type="bibr" target="#b18">[18]</ref>.</s><s>In total, 781 putative miRNA promoter regions were identified.</s><s>For detection of overlaps of genomic features (differentially methylated regions and putative miRNA promoter regions) a custom PERL script based on pair wise comparison of the genomic coordinates was used (script is available on demand).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MassARRAY DNA methylation analysis</head><p><s>DNA of formalin fixed paraffin embedded patient tissue was bisulfite converted using the Epitect Bisulfite Kit (Qiagen).</s><s>DNA methylation was quantitatively measured with the MassARRAY system (Sequenom) as previously described <ref type="bibr" target="#b19">[19]</ref>.</s><s>Primer sequences are listed in the supplementary material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro work</head><p><s>LN-308, LN-319, LN-428, D247 and U373 glioma cells were kindly provided by Prof. Nicolas de Tribolet (Lausanne, Switzerland).</s><s>LN-229, LN-18, U138 MG, T98G, A172 and U87MG cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).</s><s>Regular checks for cell line authenticity and freedom from infection, e.g.</s><s>mycoplasms, were done according to the institutional guidelines at the German Cancer Research Center.</s></p><p><s>For inhibition of DNA methylation by 5-aza-2′deoxycytidine (decitabine) cells were seeded in 6-well plates with two wells for each condition.</s><s>The cells were incubated with 0,5µM decitabine or DMSO as control treatment and the medium was exchanged every day.</s><s>T98G, U251 and U138 were treated three days and A172 and U87MG for five days.</s></p><p><s>MiR-155 (miR-155-5p) specific siRNA and control siRNA were purchased from Exiqon (Vedbaek, Denmark; miRCURY LNA Power inhibitors).</s><s>These siRNAs are based on the Locked Nucleic Acid (LNA) technology from Exiqon and feature a fully phosphorothioate (PS) modified backbone.</s><s>For stable miR-155 overexpression the glioma cell line T98G was transfected with the pre-miR-155 containing episomal vector pREP4 (Invitrogen, Carlsbad, CA, USA) for miR-155 overexpression and the prep4 backbone as control.</s><s>The ready-to-use vector was kindly provided by Jan Meier <ref type="bibr" target="#b20">[20]</ref>.</s><s>Further details on transfection procedures and assay procedures are found in the supplement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitative reverse transcription polymerase chain reaction</head><p><s>The miRNA fraction was reversely transcribed with the Universal cDNA Synthesis Kit II (Exiqon A/S, Vedbaek, Denmark) and the expression then analyzed with the miRCURY LNA™ Universal RT microRNA PCR Kit and respective primer (Exiqon) on a StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA).</s><s>miR-16 was established as reference with BestKeeper <ref type="bibr" target="#b21">[21]</ref> analysis due to is high reproducibility and low variance after the evaluation of miR-16, U6 snRNA, SNORD48, 5S RNA and let7a.</s><s>Moreover, using RNA species longer than miRNAs, e.g.</s><s>U6 snRNA, was not recommended due to potential differences in extraction and reverse transcription (e.g.</s><s>see Exiqon miRNA qPCR guidelines).</s><s>Besides, retesting the effect of decitabine demethylation using U6 as reference gene resulted in comparable effects for miR-155 expression.</s></p><p><s>RNA was transcribed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Warrington; UK) and the ABsolute qPCR SYBR Green Mix (Thermo Scientific, Waltham, USA) used for expression analysis relative to GAPDH.</s><s>Primer sequences are listed in the supplement.</s></p><p><s>The miRNA name refers to this form throughout the paper (miR-155 for miR-155-5p, miR-210 for miR-210-3p and miR-335 for miR-335-5p).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunoblot</head><p><s>Cell lysates and immunoblots were performed as described previously <ref type="bibr" target="#b22">[22]</ref>.</s><s>Antibodies: α-Tubulin 1:1000 (#3873; Cell Signaling, Cambridge, UK), β-actin 1:1000 (sc-1616; Santa Cruz, Dallas, Texas, USA), p-NF-κB p65 (L8F6) 1:1000 (#3033; Cell Signaling, Cambridge, UK); NKIRAS1 1:1000 (GTX113962; Genetex, Irvine, CA, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TCGA collective</head><p><s>Methylation (Illumina HumanMethylation450 BeadChip), miRNA expression (miRNASeq), mutational (IDH) and survival data have been obtained from The Cancer Genome Atlas dataset at April 15 th , 2013 (http:// cancergenome.nih.gov).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Microarray analysis</head><p><s>Cells were treated as described for the proliferation assay and prepared as described before <ref type="bibr" target="#b22">[22]</ref>.</s><s>The microarray data have been deposited in NCBI's Gene Expression Omnibus under accession number GSE79081.</s><s>A detailed description is found in the supplement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>MassARRAY CpG units were evaluated separately as well as averaged per amplicon.</s><s>Association of quantitative DNA methylation measurements with overall survival (OS) and progression-free survival (PFS) was assessed with univariable Cox PH regression models.</s><s>Proportional hazards assumption was tested for violation according to Grambsch and Therneau <ref type="bibr" target="#b23">[23]</ref>.</s><s>Risk groups were determined based on optimal cut-point analysis using the maximally selected log-rank statistic approach, which corrects for type I error inflation due to multiple testing <ref type="bibr" target="#b24">[24]</ref>.</s><s>Survival of risk groups was estimated with the method of Kaplan and Meier.</s><s>Univariable p-values were adjusted for multiple testing across all amplicons using Benjamini-Hochberg correction in order to control the false discovery rate <ref type="bibr" target="#b25">[25]</ref>.</s><s>Multivariable Cox regression was used to adjust for clinico-pathological factors.</s><s>All tests were two-sided.</s><s>P-values below 0.05 were considered statistically significant.</s><s>Analyses were carried out using software R Version 2.14 using add-on package rms <ref type="bibr" target="#b26">[26]</ref>.</s></p><p><s>For the TCGA data, correlation of methylation and expression was analyzed per cg probe with Pearson's correlation coefficient.</s><s>Illumina cg probes were selected to cover the MassARRAY amplicon.</s><s>For methylation data, the M value = log2 (Methylated Intensity+1) / (Unmethylated Intensity+1) was used, for miRNA expression normalized counts (reads per million miRNA mapped).</s><s>Survival analysis employed Cox proportional hazards regression and the log-rank test with maximally selected rank statistics (R package "maxstat"), which corrects for Type-I-error inflation <ref type="bibr" target="#b24">[24]</ref>.</s><s>Violation of the proportional hazards assumption was tested according to Grambsch and Therneau <ref type="bibr" target="#b23">[23]</ref>.</s><s>To adjust for type-I-error inflation, the Bonferroni procedure was used.</s><s>All tests were two-sided, and a p value &lt; 0.05 was considered significant.</s><s>Analyses were carried out using R version 3.0.2</s><s><ref type="bibr" target="#b27">[27]</ref>.</s></p><p><s>The in vitro experiments were conducted in at least three independent experiments if not otherwise indicated.</s><s>Two-sided Student's t test was applied for statistical evaluation.</s><s>Values p &lt; 0.05 were considered significant and marked with asterisks.</s><s>All error bars shown in figures represent standard deviation.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: miRNA candidates were generated by the overlay of two data sets.</s><s>The initial list of differentially methylated miRNA promoter candidates in anaplastic (anapl.)</s><s>gliomas originated from an overlay of two distinct screens: a methyl-CpG immunoprecipitation screen for differentially methylated regions in anaplastic gliomas from the NOA-04 trial (n = 4; healthy n = 1) vs. an H3K4me3 chromatin immunoprecipitation data set from cell lines of different origin (n = 6) and chronic lymphocytic leukemia patients (n = 24; healthy n = 10) for putative miRNA promoters.</s><s>From the 29 candidates (Supplementary Figure 1) produced by this overlay the 12 most favorable candidate regions were validated by MassARRAY.</s></p></div></figDesc><graphic coords="3,116.33,428.40,380.55,223.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: Low promoter methylation of miR-155, miR-210 and miR-335 was associated with a short patient survival.</s><s>Three promising miRNA candidates were selected and their Kaplan-Meier estimate from the NOA-04 patients calculated A. The statistically determined cutpoint (cut) depicts the threshold separating the patients in low and high methylation.</s><s>The number of patients in each group is listed below each graph.</s><s>Full data for all amplicons are in the supplement.</s><s>Furthermore, miRNA candidate methylation was plotted according to the IDH mutation status, molecular classification (Mol) with CpG island methylator phenotype (CIMP) and 1p/19q codeletion status [28], MGMT promoter methylation and tumor histology (histo) B. Additionally, the miRNA methylation for miR-155, miR-210 and miR-335 was correlated with the overall survival (OS) by Kaplan-Meier analysis (KM) and Cox regression in 90 patients with anaplastic gliomas available from The Cancer Genome Atlas (TCGA) C. and plotted like for the NOA-04 patients.</s><s>PFS: progression free survival; p.: individual p-value; adj.</s><s>p.: p-value adjusted for testing of multiple amplicons, CpG fragments and cutpoints; IDH: Isocitrate dehydrogenase; mut: mutated; wt: wild type; C-: CIMP negative; C+/-: CIMP positive, non-codeleted; C+/+: CIMP positive, 1p/19q codeleted; MGMT: O6methylguanine-DNA methyltransferase; m: methylated; u: unmethylated; O(A): oligodendroglioma and oligoastrocytoma; A: astrocytoma; r: Pearson's r correlation.</s></p></div></figDesc><graphic coords="4,58.20,50.40,496.80,535.17" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: miR-155 promoter methylation and expression were negatively correlated and prognostic in patients.</s><s>In a set of 12 fresh frozen anaplastic glioma samples miRNA expression was determined by qPCR and methylation by MassARRAY A. Additionally, the promoter methylation and miRNA expression was correlated in the 90 TCGA patients with anaplastic gliomas B.</s><s>Moreover, the prognostic relevance of the miRNA expression for overall survival (OS) was calculated by Kaplan-Meier analysis (KM) and Cox regression in the 90 patients from TCGA C. r: Pearson's r correlation; p.: p-value; adj.</s><s>p.: p-value adjusted for testing of multiple variables.</s></p></div></figDesc><graphic coords="5,68.26,277.20,476.69,383.92" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: miR-155 promoter methylation and expression were strong prognostic factors even in the presence of established marker.</s><s>Multivariate Cox regression models were performed to test the prognostic relevance of the miRNA methylation together with established marker.</s><s>Candidate methylation (meth.),</s><s>IDH mutation status, MGMT promoter methylation status, histopathology and first line treatment were taken into account for the NOA-04 patients (A).</s><s>From the TCGA data set the miRNA methylation and miRNA expression (expr.)</s><s>were compared against the IDH mutation status (B).</s><s>Significant correlations were denoted in grey (p-value &lt; 0.05).</s><s>Both multivariable analyses were additionally performed using the molecular classification with CpG island methylator phenotype (CIMP) and 1p/19q codeletion status (Supplementary Table4)<ref type="bibr" target="#b28">[28]</ref>.</s><s>Apart from the uni-and mulitvariable Cox regression analysis and all patients, also the Hazard ratio of the miR-155 promoter methylation (per 10% methylation increase) was calculated for the IDH wildtype and mutant patients of the NOA-04 cohort and the TCGA data.</s><s>HazR: Hazard ratio; CI: confidence interval; mut: mutated; wt: wild type; m: methylated; u: unmethylated; O(A): oligodendroglioma and oligoastrocytoma; A: astrocytoma; RT: radiotherapy; CT: chemotherapy; n: number of patients with data for all five factors; events: number of patients with progress/death.</s></p></div></figDesc><graphic coords="6,102.79,174.00,407.62,420.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 :</head><label>5</label><figDesc><div><p><s>Figure 5: miR-155 was active as onco-miRNA and conveyed therapy resistance.</s><s>miR-155 high expressing glioma cell lines (U87MG, LN-428 and A172) were transfected with scrambled (scr) and anti-miR-155 siRNA (si155) and the viability of the cells measured with AlamarBlue A. Additionally, a representative staining is shown B. Stable miR-155 overexpressing (155OE) T98G were generated and the proliferation measured in comparison to control cells (ctrl) in the Real Time Cell Analyzer (RTCA) after chemo-(TMZ) and radiotherapy treatment C.</s><s>Moreover, colony formation assays were performed with the control and 155 overexpressing T98G E. For both assays a representative experiment is given D., F. p-values &lt; 0.05 are marked by an asterisk.</s><s>TMZ: temozolomide.</s></p></div></figDesc><graphic coords="7,65.18,196.10,482.84,456.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 :</head><label>6</label><figDesc><div><p><s>Figure 6: Genes were consistently deregulated according to miR-155 expression status in patients and in vitro.</s><s>Gene expression data from patients with anaplastic gliomas of TCGA was used to calculate the degree of positive (0.4 to 1) or negative (-1 to -0.4) correlation with miR-155 expression A. The analysis was performed individually for IDH mutant (mut) and IDH wild type (wt) patients.</s><s>Each dot represents a gene and displays its correlation with miR-155 expression in IDH mutant (y-axis) and wild type patients (x-axis).</s><s>Microarray analyses were performed with control (ctrl) T98G and miR-155 overexpressing (OE) T98G after treatment with chemo-(TMZ) or radiotherapy including the respective mock treatments B. The transcriptome of the samples from three independent experiments were clustered in a heatmap.</s><s>Next, the in vitro microarray and the correlation in patients were combined to uncover relevant transcriptional changes due to miR-155 expression C. Candidates were validated by qPCR.</s><s>The microarray and qPCR data represent fold change of the gene expression from the miR-155 overexpressing cells to the control cells.</s><s>For the patient data the degree of correlation of the expression of each gene with the miR-155 expression is given.</s><s>Marked are BEX1, ATL1 and TSPAN7 with a significant miR-155 dependent down deregulation in all in vitro treatment groups and the IDH wild type patients.</s><s>An upregulated expression or positive correlation (cor.) with miR-155 expression was colored in red and the opposite in green.</s><s>Genes without data were denoted in gray.</s><s>TMZ: temozolomide; mut: mutation.</s></p></div></figDesc><graphic coords="8,76.86,190.80,459.48,384.17" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 7 :</head><label>7</label><figDesc><div><p><s>Figure 7: NFkB activation was found as common theme upon miR-155 expression.</s><s>The in vitro and patient data were analyzed with Ingenuity Pathway Analysis (IPA).</s><s>From the microarray genes consistently deregulated in all groups were used (before multiple testing correction).</s><s>The analysis revealed in both sets as upstream regulator the activation of NFκB upon miR-155 expression A. Immunoblot analysis of the p65 subunit phosphorylation (p-NFκB p65) confirmed the NFκB activation in miR-155 overexpressing (155OE) cells in comparison to control (ctrl) cells B. The cells were seeded for colony formation assay and pretreated with the NFκB inhibitor JSH-23 or DMSO as control followed by the standard chemo-(TMZ) and radiotherapy C. The ratio of colonies from miR-155 overexpressing cells (OE) to control cells (ctrl) was calculated for each treatment.</s><s>p-values &lt; 0.05 are marked by an asterisk.</s><s>NKIRAS1 was recently confirmed as miR-155 target [33].</s><s>Apart from analysis on RNA level in cells (fold change 155OE to ctrl) and patients (correlation with miR-155) D., NKIRAS1 protein levels were also determined in vitro in the control and miR-155 overexpressing cells E. cor.: correlation with miR-155 expression.</s></p></div></figDesc><graphic coords="9,98.66,268.80,415.89,339.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 8 :</head><label>8</label><figDesc><div><p><s>Figure 8: Potential association between patient survival and miR-155.</s><s>Initially, a short patient survival was correlated with a lowDNA methylation at the miR-155 promoter.</s><s>In the following, patient and in vitro data showed that an absence of this inhibitory methylation allowed the expression of miR-155.</s><s>The expression of miR-155 negatively regulated target mRNAs and led to major expression changes in the cells.</s><s>In particular, down regulation of NFκB inhibitors enabled the activation of NFκB.</s><s>This caused an increased resistance against standard clinical therapies and enabled a stronger tumor cell survival, which would explain the short patient survival.</s></p></div></figDesc><graphic coords="11,61.53,50.40,490.14,610.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="12,88.30,72.00,443.40,366.84" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>We thank Oliver Mücke for his technical assistance and support and Ann-Catherine Steffen for her technical support.</s><s>Furthermore, we want to thank Jan Meier for providing the miR-155 overexpression pREP4 plasmid.</s><s>Besides, we want to thank the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing the Illumina Whole-Genome Expression Beadchips and related services.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>There are no conflicts of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GRANT SUPPORT</head><p><s>MGS has been a scholar of the Helmholtz International Graduate School.</s><s>The work was supported by the German Cancer Aid (Deutsche Krebshilfe, "Molecular classification of anaplastic gliomas in the NOA-04 trial", project 110624) to WW and MW.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The 2007 WHO classification of tumours of the central nervous system</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ohgaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Cavenee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jouvet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Scheithauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kleihues</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta neuropathologica</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="97" to="109" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gorlia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Kouwenhoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Giangaspero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mokhtari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Mork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Paetau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reifenberger</surname></persName>
		</author>
		<author>
			<persName><surname>Van Den Bent</surname></persName>
		</author>
		<author>
			<persName><surname>Mj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of neuropathology and experimental neurology</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="545" to="551" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Noushmehr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Weisenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Diefes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pujara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Berman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Pelloski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Sulman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Bhat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rgw</forename><surname>Verhaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Hoadley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Perou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer cell</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="510" to="522" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Killela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">J</forename><surname>Reitman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bettegowda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Agrawal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jr</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gallia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Giovanella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Grollman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hruban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Jallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Mandahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="6021" to="6026" />
		</imprint>
		<respStmt>
			<orgName>Proceedings of the National Academy of Sciences of the United States of America</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Schwartzentruber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korshunov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Jones</surname></persName>
		</author>
		<ptr target="Pfaffwww.impactjournals.com/oncotarget" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma</title>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><forename type="middle">K</forename><surname>Sturm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fontebasso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Quang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Tonjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hovestadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Albrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kool</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nantel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Konermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lindroth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">482</biblScope>
			<biblScope unit="issue">7384</biblScope>
			<biblScope unit="page" from="226" to="231" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stoffels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Felsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stockhammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sabel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Koeppen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ketter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Meyermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Kortmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pietsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Ernemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">35</biblScope>
			<biblScope unit="page" from="5874" to="5880" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Koestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Houseman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Marsit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wiemels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Karagas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Wrensch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Kelsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Wiencke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the National Cancer Institute</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="143" to="153" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin</title>
		<author>
			<persName><forename type="first">A</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kharbanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Pope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">E</forename><surname>Solis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Peale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Forrest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pujara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Carrillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pandita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Ellingson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Bowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">O</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Yong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of clinical oncology</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">34</biblScope>
			<biblScope unit="page" from="4482" to="4490" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The transcriptional landscape of the mammalian genome</title>
		<author>
			<persName><forename type="first">P</forename><surname>Carninci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kasukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Katayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Frith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Oyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ravasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lenhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kodzius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shimokawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">B</forename><surname>Bajic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Batalov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Forrest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="issue">5740</biblScope>
			<biblScope unit="page" from="1559" to="1563" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Landscape of transcription in human cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Djebali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Merkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dobin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lassmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mortazavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tanzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lagarde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schlesinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Marinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Khatun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zaleski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rozowsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">489</biblScope>
			<biblScope unit="issue">7414</biblScope>
			<biblScope unit="page" from="101" to="108" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project</title>
		<author>
			<persName><forename type="first">E</forename><surname>Birney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Stamatoyannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dutta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Gingeras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Margulies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Snyder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Dermitzakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Thurman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kuehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Neph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Asthana</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Encode Project Consortium</title>
				<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">447</biblScope>
			<biblScope unit="page" from="799" to="816" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Kinetic analysis reveals successive steps leading to miRNAmediated silencing in mammalian cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bethune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Artus-Revel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Filipowicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO reports</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="716" to="723" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The role of GW182 proteins in miRNA-mediated gene silencing</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Huntzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Izaurralde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Advances in experimental medicine and biology</title>
		<imprint>
			<biblScope unit="volume">768</biblScope>
			<biblScope unit="page" from="147" to="163" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">MicroRNAs in cancer. Annual review of pathology</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dutta</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2009">2009</date>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="199" to="227" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Platten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Felsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tabatabai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nikkhah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Papsdorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Steinbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sabel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Combs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vesper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meixensberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ketter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mayer-Steinacker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Lancet Oncology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="707" to="715" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Felsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Steinbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Westphal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schackert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Tonn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Heese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Krex</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nikkhah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pietsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reifenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">34</biblScope>
			<biblScope unit="page" from="5743" to="5750" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway</title>
		<author>
			<persName><forename type="first">B</forename><surname>Goeppert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Konermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bogatyrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Geiselhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zucknick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mehrabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hafezi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Klauschen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Warth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Breuhahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Renner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="544" to="554" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Baer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Frenzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zucknick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Weichenhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Pallasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Herpel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rehli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Byrd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-M</forename><surname>Wendtner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Plass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer research</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="3775" to="3785" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Quantitative analyses of DAPK1 methylation in AML and MDS</title>
		<author>
			<persName><forename type="first">R</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hackanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Poetsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zucknick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Blagitko-Dorfs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wilop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Brummendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Galm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Platzbecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Byrd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lubbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Plass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International journal of cancer Journal international du cancer</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="E138" to="142" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNAinteracting protein-IP</title>
		<author>
			<persName><forename type="first">J</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hovestadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zapatka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pscherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seiffert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">RNA biology</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1018" to="1029" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper -Excel-based tool using pair-wise correlations</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Pfaffl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tichopad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Prgomet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Neuvians</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biotechnology Letters</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="509" to="515" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blaes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Czabanka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Luger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bunse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Solecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Eichwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jugold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hodecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Osswald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rubmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Pfenning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="409" to="414" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Proportional hazards tests and diagnostics based on weighted residuals</title>
		<author>
			<persName><forename type="first">Therneau</forename><surname>Grambsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="515" to="526" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Maximally selected rank www.impactjournals.com/oncotarget statistics</title>
		<author>
			<persName><forename type="first">B</forename><surname>Lausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="73" to="85" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Controlling the false discovery rate: a practical and powerful approach to multiple testing</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Benjamini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hochberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of the Royal Statistical Society B</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="289" to="300" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">R: A language and environment for statistical computing. R Foundation for Statistical Computing</title>
		<author>
			<persName><surname>R_Development_Core_Team</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<pubPlace>Vienna, Austria</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">R: A language and environment for statistical computing. R Foundation for Statistical Computing</title>
		<author>
			<persName><surname>R_Development_Core_Team</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<pubPlace>Vienna, Austria</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hovestadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sturm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Koelsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bertoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schweizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korshunov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Schliesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Radbruch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Herold-Mende</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Unterberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta neuropathologica</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="561" to="571" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hovestadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Felsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Platten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Feiden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Keyvani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pfister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Meyermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reifenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pietsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Deimling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro-oncology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1630" to="1638" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Mutational landscape and clonal architecture in grade II and III gliomas</title>
		<author>
			<persName><forename type="first">H</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aoki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shiozawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shiraishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shimamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Niida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Motomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ohka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tanahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ranjit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wakabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshizato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kataoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature genetics</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="458" to="468" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas</title>
		<author>
			<persName><surname>Tcga</surname></persName>
		</author>
		<author>
			<persName><surname>Comprehensive</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="2481" to="2498" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome-and transcriptome-wide profiling improves stratification of prognostically distinct patient groups</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Willscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Riehmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hentschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kreuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Felsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Löffler-Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kaulich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Steinbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gramatzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Westphal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schackert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta neuropathologica</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="679" to="693" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-kappaBdependent manner</title>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Parish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mumaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zollman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kamoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Srour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Chitteti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hogenesch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Bellido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Boswell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell stem cell</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="51" to="65" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ruppert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zucknick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Oakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Z</forename><surname>Rassenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Geyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Wierda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Gribben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Barrientos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Rai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="42" to="48" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stilgenbauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ruppert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zucknick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bühler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Oakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Jelinek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kipps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Z</forename><surname>Rassenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Gribben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Döhner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="2483" to="2491" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kostareli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Holzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bogatyrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Keck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lahrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Grabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Flechtenmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Seiwert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dyckhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Höfler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pawlita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Clinical Investigation</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2488" to="2501" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas: evidence for stage-specific events</title>
		<author>
			<persName><forename type="first">Clurman</forename><surname>Be</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Hayward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular and cellular biology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2657" to="2664" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA</title>
		<author>
			<persName><forename type="first">W</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ben-Yehuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Hayward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular and cellular biology</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1490" to="1502" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Identification of tissue-specific microRNAs from mouse</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lagos-Quintana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rauhut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yalcin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lendeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tuschl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current biology : CB</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="735" to="739" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">MicroRNAs and the advent of vertebrate morphological complexity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Heimberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Sempere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">N</forename><surname>Moy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Donoghue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Peterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2946" to="2950" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="5885" to="5894" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">The pivotal role of microRNA-155 in the control of cancer</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of cellular physiology</title>
		<imprint>
			<biblScope unit="volume">229</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="545" to="550" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncology reports</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="2111" to="2118" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tan</forename><forename type="middle">C</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of cellular biochemistry</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1213" to="1221" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">MicroRNA-155 promotes www.impactjournals.com/oncotarget glioma cell proliferation via the regulation of MXI1</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lin</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">e83055</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell biology international</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="653" to="659" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype</title>
		<author>
			<persName><forename type="first">S</forename><surname>Turcan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rohle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goenka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Awm</forename><surname>Fabius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaufman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Guryanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Heguy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Viale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">483</biblScope>
			<biblScope unit="issue">7390</biblScope>
			<biblScope unit="page" from="479" to="483" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">MGMT testing-the challenges for biomarker-based glioma treatment</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Den Bent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Von Deimling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Plass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hegi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Platten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reifenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature reviews Neurology</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="372" to="385" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Hartlieb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Schliesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Platten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Dittmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Felsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Happold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nikkhah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Papsdorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Steinbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sabel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro-oncology</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1017" to="1026" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Krichevsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kosik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer research</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="6029" to="6033" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Tumor microRNA-335 expression is associated with poor prognosis in human glioma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">X</forename><surname>Bo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Bian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Wang</forename><forename type="middle">A</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="3472" to="3477" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Identification and functional characterization of microRNAs involved in the malignant progression of gliomas</title>
		<author>
			<persName><forename type="first">B</forename><surname>Malzkorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wolter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Liesenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grzendowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stuhler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Meyer</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reifenberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain pathology</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="539" to="550" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">The somatic genomic landscape of glioblastoma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Verhaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Noushmehr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Salama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chakravarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Sanborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Berman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Beroukhim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bernard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shmulevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barnholtz-Sloan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="462" to="477" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Comprehensive genomic characterization defines human glioblastoma genes and core pathways</title>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">455</biblScope>
			<biblScope unit="issue">7216</biblScope>
			<biblScope unit="page" from="1061" to="1068" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>TCGA</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Van Der Ree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Van Nuenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Bruijne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ottosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Kootstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Reesink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alimentary Pharmacology &amp; Therapeutics</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Is miR-34a a Well Equipped swordsman to Conquer Temple of Molecular Oncology?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Farooqi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fayyaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shatynska-Mytsyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Javed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jabeen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Yaylim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Gasparri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Panici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chemical Biology &amp; Drug Design</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours</title>
		<author>
			<persName><forename type="first">N</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Vijayakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bakhshinyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Venugopal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stem cells international</title>
		<imprint>
			<biblScope unit="page">141793</biblScope>
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Andaloussi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Wood</forename><surname>Mj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Human molecular genetics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">R1</biblScope>
			<biblScope unit="page" from="R125" to="134" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">miRNA Multiplayers in glioma. From bench to bedside</title>
		<author>
			<persName><forename type="first">K</forename><surname>Rolle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta biochimica Polonica</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="353" to="365" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Methylation-specific PCR unraveled</title>
		<author>
			<persName><forename type="first">S</forename><surname>Derks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Lentjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Hellebrekers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>De Bruine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Herman</forename><forename type="middle">Jg</forename><surname>Van Engeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cellular oncology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">5-6</biblScope>
			<biblScope unit="page" from="291" to="299" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
